Greater access to denosumab and boceprevir in Canada

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.643, 2011-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Canada funds denosumab, telaprevir and rivaroxaban

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 653, 2012-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Boceprevir

Drugs in R&D, Vol. 10, Iss. 3, 2010-09 ,pp. : 203-210

Adis International

Access to resources Recommend Favorite

Embracing open access and offering greater choice for authors

Canadian Journal of Physiology and Pharmacology, Vol. 93, Iss. 6, 2015-01 ,pp. : iii-iv

NRC Research Press

Access to resources Recommend Favorite

Amgen Canada Inc. is warning of the risk of atypical femoral fracture associated with use of the osteoporosis treatment, Prolia [denosumab].

Reactions Weekly, Vol. 1, Iss. 1430, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Access to PEP for HIV infections in Canada a problem

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 520, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite